Metastatic Breast Cancer
Conditions
Keywords
Breast cancer, HER2 Positive, HER2+, MBC, Metastatic, Metastatic breast cancer, Chemotherapy, Lapatinib, Trastuzumab, anti HER2 therapies
Brief summary
Recent clinical studies have shown that the combination of lapatinib and trastuzumab has superior antitumor activity compared to either single drug in both neoadjuvant and metastatic setting and is well tolerated. According to this evidence, the combination of lapatinib and trastuzumab today offers a valid chemotherapy-free option, primarily for patients with pre-treated HER2-positive MBC
Detailed description
The present study is designed to determine the efficacy and safety profile of the combination of lapatinib and trastuzumab (plus endocrinetherapy in ER-positive breast cancer) versus trastuzumab and chemotherapy in heavily pretreated patient population with HER2-positive MBC and to investigate the predictive role of cfDNA for detection of HER2 gene amplification on patients' outcome. The presence of circulating free DNA (cfDNA) for detection of HER2 gene amplification was associated with worse prognosis and seems to allow early response evaluation. However, many aspects of the role of cfDNA detection in patients undergoing molecular target agents such as trastuzumab or lapatinib are not well described. With the availability of improved and standardized techniques for cfDNA detection, it should now be possible to examine several of these important questions within a prospective multicenter study and a striking potential of cfDNA for detection of HER2 gene amplification might enable a more individual and optimized antimetastatic therapy inpatients with cancer.
Interventions
DRUGLapatinib
ARM A: oral lapatinib 1,000 mg daily in combination with intravenous trastuzumab 6mg/kg q3wks (after the initial 8 mg/kg loading dose).
DRUGTrastuzumab
ARM A: oral lapatinib 1,000 mg daily in combination with intravenous trastuzumab 6mg/kg q3wks (after the initial 8 mg/kg loading dose).
Sponsors
Clinical Research Technology S.r.l.
Consorzio Oncotech
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histological or cytological confirmed and documented adenocarcinoma of the breast with metastatic disease * The original tumour specimen must be HER2 IHC 3+ positive or, in case of IHC 2+ * Age ≥18 * Life expectancy of \>12 weeks * ECOG PS 0-1 * Measurable disease as defined by RECIST1.1 criteria * All patients must have received prior anthracycline-and taxane-based regimens as well as trastuzumab based regimens in either the adjuvant or the metastatic setting. Patients must have been already treated with at least one line of the anti HER2 inhibitor therapy lapatinib for their metastatic breast cancer. A maximum of three previous lines of anti-HER-2 therapies in the metastatic setting are allowed. * Adequate haematological function as defined by: ANC 1.5 x 109/L, platelet count 100 x 109/L, haemoglobin 10 g/dL. * Adequate renal function, as defined by: creatinine 1.5 x UNL * Adequate hepatobiliary function, as defined by the following baseline liver function tests: total serum bilirubin 1.5 upper normal limit (UNL); alanine amino transferase (ALT), aspartate amino transferase (AST) 2.5xUNL; alkaline phosphatase (AP) 2.5xUNL; if total alkaline phosphatase (AP) \> 2.5xUNL, alkaline phosphatase liver fraction must be 2.5xUNL * Adequate contraception for all fertile patients * Negative pregnancy test. * Postmenopausal women fulfilling any of the NCCN criteria may be included. * Left ventricular ejection fraction (LVEF) ≥50% during a baseline period of 28 days, as determined by either echocardiography (ECHO) or multi gated acquisition (MUGA) scan. * Signed, written informed consent
Exclusion criteria
* History of persistent Grade ≥ 2 hematologic toxicity resulting from previous systemic therapy * Current peripheral neuropathy of NCI-CTCAE, Version 3.0, Grade ≥ 3 at randomization * History of other malignancy within the last 5 years, except for carcinoma in situ of the cervix or basal cell carcinoma * Bone-only disease, unless a measurable lesion is evident as determined by RECIST v1.1 * Bone scan, PET scan or plain films are not considered adequate imaging techniques to measure bone lesions. ve * Blastic bone lesions are non-measurable. * Uncontrolled hypertension (systolic \>150 mm Hg and/or diastolic \>100 mm Hg) or clinically significant (i.e. active) cardiovascular disease. * Current dyspnoea at rest due to complications of advanced malignancy, or other diseases that require continuous oxygen therapy. * Inadequate organ function, evidenced by the following laboratory results within 28 days prior to randomization. * Current severe, uncontrolled systemic disease * Major surgical procedure or significant traumatic injury within 28 days prior to study treatment start or anticipation of the need for major surgery during the course of study treatment * History of receiving any investigational treatment within 28 days of randomization * Current known infection with HIV, HBV, or HCV * Receipt of IV antibiotics for infection within 14 days of randomization * Known hypersensitivity to any of the study drugs * Assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol * Lack of physical integrity of the upper gastrointestinal tract, clinically significant malabsorption syndrome, or inability to take oral medications * Concurrent interventional or non-interventional studies
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clinical Benefit Rate | Clinical Benefit Rate is defined as confirmed complete response plus partial response at any time, plus stable disease up to 24 weeks | To evaluate clinical benefit rate (CBR) for patients treated with lapatinib and trastuzumab and for patients treated with trastuzumab and chemotherapy. CBR is defined as: confirmed complete response (CR) plus partial response (PR) at any time, plus stable disease (SD) for 24 weeks |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression free survival | Patients enrolled will receive study medication until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever comes first, assessed up to 36 months | Second-line progression-free survival, defined as the time from first dosing to the first documented disease progression or death from any cause, whichever occurs first. |
| Overall Survival | Patients enrolled will receive study medication until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever comes first, assessed up to 36 months | OS is defined as the time from first dosing in second line to death from any cause. |
| Safety and tolerability | Patients enrolled will receive study medication until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever comes first, assessed up to 36 months | Safety of second line treatment will be evaluated by the frequency of AEs and SAEs, cardiac events, clinically significant abnormal laboratory tests, vital signs, and ECOG PS. All patients who received at least one dose of study treatment will be included in the safety analysis. |
| Quality of life | Patients enrolled will receive study medication until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever comes first, assessed up to 36 months | QoL and symptom control will be assessed using the FACT-B questionnaire. |
Countries
Italy
Contacts
Primary ContactClinical Research Technology
Outcome results
None listed